In patients with non-liver progression, next-generation ALKis might be the preferred treatment option. and 10.8 months with chemotherapy, respectively, P=0.019). However, crizotinib continuation plus local…
The status of each of the above items was listed as yes to indicate a low risk, no to indicate a high risk or unclear…
2002;108:98C106. siRNA) and Gq-independent (not blocked by glycoprotein [GP] 2A, a Gq inhibitor, or Gq siRNA). PLC- activation and cell migration was blocked by siRNA…